Application of crispr/cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma egfr testing in patients with non-small cell lung cancer

HIGHLIGHTS

SUMMARY

The authors validated and optimized CRISPR-CPPC assay to overcome the challenges of using cfDNA and demonstrated its efficacy in detecting a low copy number of T790M mutation in cfDNA of TKIresistant patients. The analytical performance of detecting EGFR T790M (NM_005228.4:c.2369C>T, p.Thr790Met) was evaluated by comparing the results of CRISPR-CPPC assay to those of qPCR or ddPCR. The authors used ddPCR as a downstream application for detecting T790M, and the nomenclature is established as follows: "ddPCR" means ddPCR without CRISPR-CPPC, and "CRISPRCPPC assay" means CRISPR-CPPC analyzed . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.